Latest news with #therapeutics
Entrepreneur
2 days ago
- Health
- Entrepreneur
MIT Biology Team develops FragFold computational method
Researchers from MIT's Department of Biology have developed a new computational method called FragFold, which shows promise for advancing biological research and therapeutic applications. The newly created tool represents a... This story originally appeared on Calendar Researchers from MIT's Department of Biology have developed a new computational method called FragFold, which shows promise for advancing biological research and therapeutic applications. The newly created tool represents a step forward in computational biology, offering scientists additional resources for understanding complex biological systems. According to the research team, FragFold's capabilities could help address current challenges in biological research while potentially opening new avenues for therapeutic development. How FragFold Works While specific technical details about FragFold's functioning remain limited, the computational method appears to process biological data in ways that could benefit researchers across multiple disciplines. The MIT Biology team behind the innovation has indicated that the method can analyze biological fragments and predict folding patterns, which is critical for understanding protein structures and functions. Proteins, the workhorses of cellular function, depend on their three-dimensional structure to perform their roles correctly. The ability to predict how these structures form has been a long-standing challenge in molecular biology. FragFold may offer new approaches to this problem. Research Applications The primary value of FragFold lies in its research applications. Scientists studying fundamental biological processes may use this computational method to: Predict protein structures from sequence data Analyze interactions between biological molecules Model complex biological systems Generate hypotheses for experimental testing These capabilities could accelerate discovery in fields ranging from basic cell biology to evolutionary studies. By providing computational predictions, FragFold may help researchers prioritize experiments and focus their laboratory work on the most promising directions. Therapeutic Potential Beyond basic research, FragFold shows potential for therapeutic applications. Drug discovery often relies on understanding how potential medications interact with their biological targets, typically proteins. By improving predictions of protein structures and interactions, FragFold could help pharmaceutical researchers identify new drug candidates or optimize existing ones. Computational methods like this can significantly reduce the time and resources needed in early-stage drug discovery,' noted one researcher familiar with similar technologies. 'The ability to accurately predict how molecules interact can mean fewer failed candidates and faster development timelines.' The therapeutic applications might extend to personalized medicine, where understanding how genetic variations affect protein structure could help predict individual responses to treatments. Challenges and Limitations As with any computational method, FragFold likely faces limitations in accuracy and scope. Biological systems are notoriously complex, and computational predictions require experimental validation. The MIT team has not yet published comprehensive validation studies showing how FragFold compares to existing methods in the field. Additionally, computational resources required to run such analyses can be substantial, potentially limiting access for some research groups without high-performance computing capabilities. The development of FragFold adds to a growing toolkit of computational methods in biology. As researchers continue to refine these approaches and integrate them with experimental data, our understanding of biological systems is likely to deepen, potentially leading to new insights and therapeutic strategies for addressing human diseases. The post MIT Biology Team develops FragFold computational method appeared first on Calendar.
Globe and Mail
3 days ago
- Business
- Globe and Mail
Meningioma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Meningioma Pipeline Insight 2025' report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Meningioma pipeline landscape. It covers the Meningioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Meningioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Meningioma Pipeline. Dive into DelveInsight's comprehensive report today! @ Meningioma Pipeline Outlook Key Takeaways from the Meningioma Pipeline Report In May 2025, European Organisation for Research and Treatment of Cancer - EORTC conducted a LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision medicine "theranostic" concept of combining diagnostic patient selection using PET-based molecular imaging and target-specific therapeutic intervention using a systemically administered radioligand. In May 2025, Baptist Health South Florida announced a phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma. DelveInsight's Meningioma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Meningioma treatment. The leading Meningioma Companies such as NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others. Promising Meningioma Pipeline Therapies such as Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others. Stay ahead with the most recent pipeline outlook for Meningioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Meningioma Treatment Drugs Meningioma Emerging Drugs Profile Gleolan: NX Devolopment Corp NX development corp.'s drug, Gleolan also known as Aminolevulinic acid is an orally administered small molecule in development for the treatment and real time detection of meningioma. Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The exogenous application of ALA leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light. It is a photosensitizer molecule which can utilize the energy to induce photochemical reactions to produce lethal toxic agents; ultimately results in cell death and tissue destruction. Nivolumab: Bristol-Myers Squibb Bristol-Myers Squibb 'breakthrough' drug nivolumab is currently being evaluated for the treatment of Meningioma and has demonstrated good safety and efficacy profile in phase II trials. Nivolumab is a human immunoglobin (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks the interaction with PD-L1 and PD-L2, releasing anti-tumor response. The Meningioma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Meningioma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Meningioma Treatment. Meningioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Meningioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Meningioma market Explore groundbreaking therapies and clinical trials in the Meningioma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Meningioma Drugs Meningioma Companies NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others. Meningioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Intramuscular Molecule Type Meningioma Products have been categorized under various Molecule types such as Small molecules Natural metabolites Monoclonal antibodies Product Type Unveil the future of Meningioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Meningioma Market Drivers and Barriers Scope of the Meningioma Pipeline Report Coverage- Global Meningioma Companies- NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others. Meningioma Pipeline Therapies- Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others. Meningioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Meningioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Meningioma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Meningioma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Meningioma: Overview Pipeline Therapeutics Therapeutic Assessment Meningioma – DelveInsight's Analytical Perspective In-depth Commercial Assessment Meningioma Collaboration Deals Late Stage Products (Phase III) Gleolan: Nx Development Corp. Drug profiles in the detailed report….. Mid Stage Products (Phase II) Nivolumab: Bristol-Myers Squibb Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products Drug profiles in the detailed report….. Inactive Products Meningioma Key Companies Meningioma Key Products Meningioma- Unmet Needs Meningioma- Market Drivers and Barriers Meningioma- Future Perspectives and Conclusion Meningioma Analyst Views Meningioma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
National Post
3 days ago
- Business
- National Post
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
Article content Article content Article content CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced positive preclinical results for its lead neuroplastogen drug candidate, EB-003, in the Open Space Forced Swim Test, a preclinical mouse model of severe depression and despair. Article content The Open Space Forced Swim Test, a well-established psychiatric behavioral model, is designed to induce potent and enduring chronic depression-like states in mice, leading to reduced swim distance and increased periods of despair-induced immobility. In a study performed by a third-party lab, an oral dose of EB-003 at 30 mg/kg significantly reduced depression-like behavior within 30 minutes of administration. This was indicated by the enhanced distance travelled and reduced immobility of treated mice during forced swim sessions (statistical p-value < 0.01). These results were comparable to the therapeutic effects of Imipramine, an approved tricyclic antidepressant drug. Article content A repeat study, conducted by the same third-party lab, produced consistent results, confirming 30 mg/kg as an efficacious oral dose for EB-003. The study also confirmed no adverse locomotor effects were observed at this dose. Article content The study also performed a preliminary assessment of extended, daily dosing of EB-003 to determine any potential safety concerns for chronic therapeutic administration. Mice receiving a daily oral dose of EB-003 at 30 mg/kg for 22 days showed no adverse behavioral, physiological or neurological effects. These observations demonstrate acceptable tolerance to long-term systemic drug exposure and expand the range of EB-003 dosing strategies. Article content 'We are encouraged by these statistically significant and biologically meaningful results in a severe chronic depression animal model,' said Dr. Joseph Tucker, CEO of Enveric Biosciences. 'EB-003 has now demonstrated strong behavioral efficacy and a clean safety profile in several animal models that are relevant to chronic treatment of severe depression. These data points validate the compound's pharmacological design and provide strong support for the planned Investigational New Drug (IND) application' Article content EB-003 is the lead compound from Enveric's proprietary EVM301 Series, a pipeline of next-generation neuroplastogens engineered to stimulate synaptic plasticity without incurring hallucinogenic liability. Article content About Enveric Biosciences Article content Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development platform Psybrary™, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Article content This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. Article content A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Article content Article content Article content Article content Article content Contacts Article content Investor Relations Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 dirish@ Article content Article content Article content
Associated Press
23-05-2025
- Business
- Associated Press
$8.5 Bn Epigenetics Markets, 2021-2024 & 2025-2029 - Increasing Investment in Biomedical Research, Trends Towards Precision Medicine, Growing Interest in Liquid Biopsy
DUBLIN--(BUSINESS WIRE)--May 23, 2025-- The 'Epigenetics Market' report has been added to offering. The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029. This report comprehensively analyzes the global market for epigenetics products, research tools and reagents, epigenetic biomarker-based in vitro diagnostics (IVDs) and epigenetics-targeted therapeutics. It offers both quantitative and qualitative insights to help readers formulate growth strategies, evaluate the market landscape, assess their competitive positions and make informed business decisions regarding epigenetics products and services. The scope of epigenetics-targeted therapeutics includes DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, isocitrate dehydrogenase (IDH) inhibitors and zeste homolog 2 (EZH2) inhibitors. Epigenetics is the study of heritable changes in gene expression or activity that do not involve alterations to the DNA sequence itself. The global market for epigenetics research tools and reagents by study method was estimated at $1.8 billion in 2023. This market should reach $2.2 billion by the end of 2029, growing at a CAGR of 4.1% through the forecast period. The demand for new research tools remains constant as scientists strive to advance understanding and pursue groundbreaking discoveries. The mounting clinical evidence supporting the relevance of epigenetics in various diseases has fueled a surge in epigenetic research, thereby increasing the demand for high-quality reagents and research tools. The trend is expected to continue over the forecast period, yielding market growth. Epigenetic therapeutics target and modulate epigenetic mechanisms to restore a more normal epigenomic configuration. The global market for epigenetic therapeutics market by drug class targeting DNMT, IDH, HDAC and EZH2 was estimated at $938.2 million in 2023. The market is expected to reach $1.9 billion by the end of 2029, growing at a CAGR of 11% over the forecast period. Emerging research demonstrates the potential of epigenetics-based therapeutics as a versatile and targeted treatment modality, offering a viable alternative to conventional chemotherapy. Scientific advances, the growing number of cancer patients and the unmet need in oncology are key growth factors of the epigenetic drugs market. The report includes: Company Profiles Key Attributes: Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Market Overview Chapter 3 Market Dynamics Chapter 4 Emerging Technologies and Developments Chapter 5 Market Segmentation Analysis Chapter 6 Competitive Intelligence Chapter 7 Sustainability in the Epigenetics Market: An ESG Perspective Chapter 8 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY GENETICS HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 05/23/2025 12:16 PM/DISC: 05/23/2025 12:16 PM
Yahoo
23-05-2025
- Business
- Yahoo
Enliven Therapeutics to Present at Upcoming Investor Conferences
BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences: TD Cowen's 6th Annual Oncology Innovation Summit: Insights from ASCO & EHAFormat: Fireside ChatDate: Tuesday, May 27, 2025Time: 1:00 p.m. ET Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, June 4, 2025Time: 4:20 p.m. ET Goldman Sachs Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, June 10, 2025Time: 4:00 p.m. ET The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at Each webcast will be archived for a period of 90 days following the conclusion of the live event. About Enliven TherapeuticsEnliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado. View original content to download multimedia: SOURCE Enliven Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
